- Home
- ATLC vs CDMO Comparison
ATLC vs CDMO Comparison
Compare ATLC & CDMO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ATLC
- CDMO
- Stock Information
- Founded
- ATLC 1996
- CDMO 1981
- Country
- ATLC United States
- CDMO United States
- Employees
- ATLC N/A
- CDMO N/A
- Industry
- ATLC Finance: Consumer Services
- CDMO Biotechnology: Pharmaceutical Preparations
- Sector
- ATLC Finance
- CDMO Health Care
- Exchange
- ATLC Nasdaq
- CDMO Nasdaq
- Market Cap
- ATLC 826.6M
- CDMO 793.8M
- IPO Year
- ATLC 1999
- CDMO N/A
- Fundamental
- Price
- ATLC $58.91
- CDMO $12.46
- Analyst Decision
- ATLC Strong Buy
- CDMO Hold
- Analyst Count
- ATLC 5
- CDMO 3
- Target Price
- ATLC $57.20
- CDMO $12.25
- AVG Volume (30 Days)
- ATLC 49.9K
- CDMO 1.3M
- Earning Date
- ATLC 03-03-2025
- CDMO 12-10-2024
- Dividend Yield
- ATLC N/A
- CDMO N/A
- EPS Growth
- ATLC 8.45
- CDMO N/A
- EPS
- ATLC 4.45
- CDMO N/A
- Revenue
- ATLC $374,090,000.00
- CDMO $150,445,000.00
- Revenue This Year
- ATLC N/A
- CDMO $19.05
- Revenue Next Year
- ATLC $12.99
- CDMO $20.88
- P/E Ratio
- ATLC $13.40
- CDMO N/A
- Revenue Growth
- ATLC 8.50
- CDMO 6.75
- 52 Week Low
- ATLC $23.10
- CDMO $5.90
- 52 Week High
- ATLC $64.70
- CDMO $12.48
- Technical
- Relative Strength Index (RSI)
- ATLC 57.29
- CDMO 66.88
- Support Level
- ATLC $52.45
- CDMO $12.37
- Resistance Level
- ATLC $60.89
- CDMO $12.45
- Average True Range (ATR)
- ATLC 2.21
- CDMO 0.05
- MACD
- ATLC 0.14
- CDMO -0.01
- Stochastic Oscillator
- ATLC 76.54
- CDMO 100.00
About ATLC Atlanticus Holdings Corporation
Atlanticus Holdings Corp invests in the financial services industry. It provides various credit and related financial services and products to or associated with the financially underserved consumer credit market. The operating business segments are the Credit as a Service and the Auto Finance segment. It generates maximum revenue from the Credit as a Service segment.
About CDMO Avid Bioservices Inc.
Avid Bioservices Inc is a clinical-stage biopharmaceutical company focused on the development and Current Good Manufacturing Practices (CGMP) of biopharmaceutical products derived from mammalian cell culture. Its business is organized into one reportable operating segment which is contract manufacturing and development services segment. Its services include clinical and commercial drug substance manufacturing, bulk packaging, release and stability testing and regulatory submissions support. The company also provides a variety of process development services including cell line development, upstream and downstream development and optimization, analytical method development, testing and characterization.